BioCentury
ARTICLE | Company News

Agensys, Astellas deal

December 3, 2007 8:00 AM UTC

Astellas will acquire Agensys for $387 million in cash, net of Agensys' $30 million in cash. Agensys shareholders also are eligible for $150 million in milestones. Agensys' lead compound is AGS-PSCA, which is in Phase Ib testing to treat prostate cancer. The human IgG1k MAb against prostate stem cell antigen (PSCA) is partnered with Merck & Co. Inc. (MRK, Whitehouse Station, N.J.). Agensys also has 30 target antigens in 14 cancer types identified by gene expression monitoring of human tumor tissue samples. ...